Description
Chonluten is a synthetic tripeptide bioregulator developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is the respiratory system representative of the Khavinson bioregulator series. As such, it targets bronchopulmonary epithelial cells with the same intranuclear DNA-binding mechanism that characterizes the broader peptide class. Chonluten enters bronchial epithelial cell nuclei and binds specific promoter regions, modulating the expression of stress-response and inflammatory genes, including c-Fos, HSP70, SOD, COX-2, and TNF-alpha in respiratory tissue models. This gene-level targeting distinguishes it from receptor-mediated respiratory research tools and positions it as a tool for studying bronchopulmonary epithelial gene regulation directly. Researchers working across the Khavinson specialty research peptide series often include Chonluten alongside tissue-specific bioregulators targeting other organ systems.
Chemical Information
- Chemical Name: Chonluten (Khavinson bronchial epithelium-derived tripeptide bioregulator)
- Also Known As: Chonluten peptide complex; bronchopulmonary tripeptide bioregulator
- Compound Class: Short-chain synthetic tripeptide; tissue-specific epigenetic bioregulator (Khavinson series)
- Sequence: No data
- Molecular Formula: Not established in public literature
- Molecular Weight: Not established in public literature (consistent with the broader Khavinson class of low molecular weight peptides, <10,000 Da)
- CAS Number: Not established in public literature
Applications
- Bronchopulmonary and airway epithelium research. As a bioregulator modeled on bronchial epithelial tissue, researchers use Chonluten to examine bronchial epithelial cell regulation, repair signaling, and tissue-specific gene expression programs. It is the same experimental tradition as other organ-targeted Khavinson bioregulators such as Cardiogen (cardiac) and Cartalax (cartilage)
- Monocyte/macrophage inflammatory signaling research. Published in vitro work using the human THP-1 monocytic cell line found that Chonluten reduced LPS-stimulated TNF and IL-6 output and reduced monocyte adhesion to activated endothelial cells, alongside four other Khavinson peptides (Epithalon, Vilon, Thymogen, Thymalin) tested in the same model — researchers use this shared dataset to compare relative anti-inflammatory and TNF-tolerance-inducing effects across the bioregulator family
- Comparative bioregulator-class research. Chonlutein shares its proposed DNA-interaction mechanism with other short-chain Khavinson peptides. Therefore it is used alongside tissue-matched and mismatched bioregulators (e.g., Cortagen for cortex, Cardiogen for cardiac tissue) to study whether the anti-inflammatory and gene-regulatory effects observed are tissue-general or tissue-restricted
- Note on evidence base: Published data on Chonluten are mostly in Russian-language and Khavinson-network literature, largely preclinical and in vitro.
Storage and Handling
Store lyophilized powder under refrigeration (2-8C), protected from heat, light, and moisture. As a short-chain peptide, Chonluten is susceptible to proteolytic degradation once reconstituted. Reconstitute immediately before use, keep reconstituted solution refrigerated, and avoid repeated freeze-thaw cycles.
Compliance Notice
Chonluten is for laboratory research use only. It is not for human or veterinary use and carries no therapeutic, diagnostic, or clinical indication. This product has not been evaluated by the FDA. By purchasing this product, the buyer confirms that they will follow appropriate institutional safety procedures and use it exclusively for controlled research.
